Enzyvant Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
Enzyvant is a Cambridge, Massachusetts-based biotechnology company with 11-50 employees, focused on regenerative medicines for rare diseases. It encompasses non-clinical and clinical development, commercialization, and in-house manufacturing capabilities, and it collaborates with academia, industry, physician associations, advocacy groups, and government partners to advance transformative therapies. Enzyvant notes achievements in regenerative medicine, including delivering one of the first Regenerative Medicine Advanced Therapy products and pursuing advances in immunology and cardiopulmonology. Recent corporate activity includes acquiring Altavant Sciences Ltd. in July 2023, with a merger/partnership with Altavant announced in 2022. The information indicates the page is no longer active and that the successor entity is Sumitomo Pharma America (SMPA); the company’s website is enzyvant.com.